Our partner is developing novel pan-amyloid removal (PAR) therapeutics that directly bind to and remove toxic amyloid, opening the potential to treat and reverse disease in all types of systemic amyloidosis. Their proprietary technology has enabled them to develop novel biologics, as well as the world’s first amyloidosis-specific imaging agent that propel their strategy to identify and treat all stages and types of patients with this life-threatening disease.

This senior leader has immense cross-functional CMC expertise and was critical to helping our partner achieve their long-term growth plan. Their experience leading highly productive and collaborative teams across CMC functions, was beneficial for our partner as they grew from a research and development company to a commercial-stage organization.